Yiheng Capital Management L.P. Makes New $3.36 Million Investment in Kymera Therapeutics, Inc. $KYMR

Key Points

• Yiheng Capital Management L.P. has acquired 122,605 shares of Kymera Therapeutics, Inc. ($KYMR), worth approximately $3.36 million, making it the 16th largest position in their portfolio.
• Director Bvf Partners L.P./Il has increased their stake in Kymera by acquiring 317,167 shares for a total of $13.96 million, bringing their total ownership to approximately 2.8 million shares.
• Kymera Therapeutics reported a loss of ($0.95) EPS in its last earnings announcement, falling short of expectations, with revenues significantly declining by 55.1% from the previous year.

Yiheng Capital Management L.P. purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 122,605 shares of the company's stock, valued at approximately $3,356,000. Kymera Therapeutics accounts for about 0.3% of Yiheng Capital Management L.P.'s portfolio, making the stock its 16th biggest position. Yiheng Capital Management L.P. owned about 0.19% of Kymera Therapeutics as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in KYMR. State of Wyoming acquired a new position in Kymera Therapeutics during the 4th quarter worth $45,000. GF Fund Management CO. LTD. acquired a new position in Kymera Therapeutics during the 4th quarter worth $55,000. KBC Group NV boosted its position in Kymera Therapeutics by 15.2% during the 1st quarter. KBC Group NV now owns 2,479 shares of the company's stock worth $68,000 after acquiring an additional 328 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics during the 1st quarter worth $68,000. Finally, GAMMA Investing LLC boosted its position in Kymera Therapeutics by 3,851.5% during the 1st quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock worth $183,000 after acquiring an additional 6,509 shares during the period.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock traded down $2.40 during mid-day trading on Thursday, hitting $40.91. The company's stock had a trading volume of 350,824 shares, compared to its average volume of 737,823. The firm's 50 day moving average is $43.46 and its 200 day moving average is $36.91. The company has a market cap of $2.92 billion, a PE ratio of -11.80 and a beta of 2.17. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The business had revenue of $11.48 million during the quarter, compared to analysts' expectations of $17.37 million. Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The firm's revenue was down 55.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.58) earnings per share. As a group, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wells Fargo & Company decreased their target price on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, June 26th. Jefferies Financial Group set a $64.00 target price on Kymera Therapeutics and gave the company a "buy" rating in a research note on Wednesday, June 25th. HC Wainwright reaffirmed a "buy" rating and set a $60.00 target price (up previously from $54.00) on shares of Kymera Therapeutics in a research note on Thursday, June 26th. Guggenheim reaffirmed a "buy" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, June 3rd. Finally, B. Riley raised Kymera Therapeutics to a "strong-buy" rating and set a $60.00 target price for the company in a research note on Wednesday, July 30th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $58.76.

Insider Activity

In other news, Director Bvf Partners L. P/Il bought 317,167 shares of the company's stock in a transaction on Monday, June 30th. The shares were bought at an average cost of $44.00 per share, with a total value of $13,955,348.00. Following the transaction, the director directly owned 2,798,795 shares in the company, valued at approximately $123,146,980. This trade represents a 12.78% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bros. Advisors Lp Baker acquired 655,500 shares of the stock in a transaction dated Monday, June 30th. The shares were bought at an average cost of $44.00 per share, for a total transaction of $28,842,000.00. Following the acquisition, the director owned 6,117,295 shares in the company, valued at $269,160,980. The trade was a 12.00% increase in their position. The disclosure for this purchase can be found here. 16.01% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.